# A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Study · id `cardio:ct-nct05930028` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05930028](<https://clinicaltrials.gov/study/NCT05930028>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05930028

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

## Technical summary

Registry record NCT05930028. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2024-09-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 148 participants (enrolled count; ClinicalTrials.gov record NCT05930028, source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)
- Started: 2023-07-13 (actual) (ClinicalTrials.gov record NCT05930028, source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)
- Primary completion: 2024-09-05 (actual) (ClinicalTrials.gov record NCT05930028, source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)
- Completion: 2024-09-05 (actual) (ClinicalTrials.gov record NCT05930028, source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05930028, source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05930028-2024-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
- Condition: Essential Hypertension
- Condition: Primary Hypercholesterolemia
- Intervention (Drug): Fimasartan
- Intervention (Drug): Ezetimibe/Atorvastatin
- Intervention (Drug): Fimasartan Placebo
- Intervention (Drug): Ezetimibe/Atorvastatin Placebo
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: a3c59d2f97e300ad25a57b1ffff13695502c1b4552499391f1915a732acc1340
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
